To date, the role of GSK-3 in the regulation of activating ligands on leukemia cells remains unclear, given the results of a previous study that only used pharmacological agents for GSK-3 inhibition and only assessed the limited ligands (i.e., MICA/B and PVR/CD155) for NKG2D and DNAM-1 [28]. This evidence concerns the gene PVR and leukemia.